Cambridge Healthtech Institute’s 6th Annual

Disease Modeling  

Developing, Validating, Scaling, and Automating Physiologically Relevant Disease Models

June 2-4, 2020


Inadequate representation of the human tissue environment during a preclinical screen can result in inaccurate predictions of a drug candidate’s effects. Thus, investigators are searching for preclinical models that closely resemble original tissue for predicting clinical outcome. With advances in reprogramming and differentiation technologies, as well as with the recent availability of gene editing approaches, we are finally able to create more complex and phenotypically accurate models that span all therapeutic areas. At Cambridge Healthtech Institute's 6th Annual Disease Modeling conference, we will discuss the next generation of models, as well as strategies to overcome common bottlenecks, such as standardization, scaling, and workflow integration.

MOVING TOWARDS A 3D PHYSIOLOGICALLY RELEVANT CELLULAR MODEL

Combining 3D Models and Functional Genomics in Preclinical Drug Development
Alejandro Amador, PhD, Scientific Leader, Platform Biology Automation, GSK

Adult Stem Cell Organoids: A Patient in the Lab
Robert Vries, PhD, CEO, Hubrecht Organoid Technology (HUB)

Talk to Be Announced

Joanna Lee, PhD, Scientist, Genentech

3D Enteroid-Derived “Gut-in-a-dish” Model for Developing Personalized Therapies for Chronic Inflammatory Diseases
Soumita Das, PhD, Associate Professor, Department of Pathology, Chief Scientific Director, HUMANOID Center of Research Excellence (CoRE), University of California, San Diego

3D Models of Brain Cancer for Precision Medicine Therapeutic Profiling
Virneliz Fernandez Vega, Scientific Associate, Scripps Research

Development of a Miniaturized 3D Organoid Culture Platform for ultra-High-Throughput Screening (uhTS)
Yuhong Du, PhD, Associate Professor, Department of Pharmacology and Chemical Biology, Associate Director, Emory Chemical Biology Discovery Center (ECBDC), Emory University School of Medicine

CO-PRESENTATION: Advanced Peptide Hydrogels for 3D Model, Lab-on-Chip, and hiPSCs
Susan Sun, Chief Technical Officer, PepGel LLC

Todd Ringhouse, General Manager, PepGel LLC

BRIDGING LUNCHEON PRESENTATION: Talk Title to be Announced
Nicholas Geisse, PhD, CSO, NanoSurface Biomedical

IPSC-BASED MODELS FOR DISEASE MODELING

FEATURED TALK: Talk to be Announced

Lisa Mohamet, PhD, Scientific Leader Drug Design & Selection, Department, GSK

 

Development of Patient-Derived iPSC Models and Phenotypic Assays for Early Drug Discovery in Neuroscience
Yoshiyuki Tsujihata, PhD, Director, Phenotypic Reverse Translation Lab, Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited

Of Microtissues and Men: Applications of Advanced In Vitro Systems in Toxicology

Matthew Wagoner, PhD, Director of Investigative Toxicology, Takeda Pharmaceutical

 

Reconstruction of the Human Blood-Brain Barrier in vitro Reveals the Pathogenic Mechanisms of ApoE4 in Cerebral Amyloid Angiopathy
Joel Blanchard, PhD, Postdoctoral Fellow, Picower Institute for Learning and Memory, MIT

BIOENGINEERED MODELS

KEYNOTE PRESENTATION: Talk to Be Announced

Linda Griffith, PhD, School of Engineering Professor of Teaching Innovation, Biological Engineering, and Mechanical Engineering

 

IQ MPS Consortium Update

Szczepan Baran, Head of Emerging Technologies, LAS, SO, Novartis

 

Biofabrication of 3D Tissues for Disease Modeling and Drug Screening
Marc Ferrer, PhD, Leader, Biomolecular Screening and Probe Development, Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health (NIH)

Gut Organoid Models We Are Building from Healthy Adult Stem Cells
Linda Lieberman, PhD, Principal Scientist, Merck Exploratory Science Center

Neuromuscular Junction on-a-Chip Model
Graham Marsh, PhD, Scientist, Biogen